Table 2 Patient clinical outcomes

MmsHD change at 3 months

− 3

− 6

− 9

− 9

− 2

− 6

− 4

− 5.6 (2.8)

p = 0.002

MmsHD change at relapse

− 5

− 13

− 6

− 13

− 7

− 10

− 6

−8.6 (3.4)

p < 0.001

MHD change at 3 months

− 20

0

− 18

− 12

− 15

−16

− 4

−12.1 (7.4)

p = 0.028

MHD change at relapse

− 22

0

0

−15

− 10

− 24

− 5

− 10.9 (9.9)

p = 0.043

Headache severity (NRS) change at 3 months

2

−0.9

0.2

−2.6

0.1

0.1

−1.7

−0.4 (1.5)

p = 0.497

Headache severity (NRS) change at relapse

2.7

−1.4

−0.8

−2.7

− 1.8

− 0.4

−2.4

− 1.0 (1.8)

p = 0.253

Monthly analgesic days change at 3 months

3

−1

− 6

− 18

0

− 4

−9

− 5.0 (7.0)

p = 0.107

Monthly analgesic days change at relapse

0

0

−5

−18

−7

1

−10

−5.6 (6.9)

p = 0.075

HIT-6 score change at 3 months

− 5

−11

− 4

− 13

1

− 8

2

− 5.4 (5.7)

p = 0.045

HIT-6 score change at relapse

− 5

− 13

−4

−3

0

−18

− 2

−6.4 (6.6)

p = 0.041

Frisén grade at relapse (worst eye)

4

2

3

1

1

1

1

1.9 (1.2)

OCT global average RNFL thickness at relapse worst eye (μm) ^a

326 ^b

140 ^b

174 ^b

132 ^c

116 ^c

151 ^c

202 ^c

177.3 (71.4)

p = 0.043

BMI at relapse

31.3

48.5

38.7

38

44.6

36.7

30.5

38.3 (6.5)

p = 0.025

BMI change

0.3

2.3

3.5

0.7

2.5

7.3

1.7

2.6 (2.3)

IIH characteristics at relapse

B, T, V

B, T

B, T, V

B, D, T

B, D, T

B, D, T

B, T

Side effects

CO

HT, I

I

CO, MC